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Androgen blockade-naïve prostate cancer (PCa) develops into CRPC during androgen 
deprivation therapy (ADT) by various genetic actions. The androgen-AR signaling axis 
plays a key role in this development. PCa cells mainly adapt themselves to the 
environment of lower androgen concentrations and change into androgen-hypersensitive 
cells or androgen-independent cells. Androgens of adrenal origin and their metabolites 
synthesized in the microenvironment in an intracrine/paracrine fashion act on surviving 
PCa cells and secrete prostate specific antigen (PSA). Total androgen deprivation (TAD) 
(castration, antiandrogen, and CYP17A1 inhibitor) can become an effective therapeutic 
strategy concerning the androgen signaling axis-related pathway. However, it is 
important to ascertain whether elevation of serum PSA results from AR activation or 
from an androgen-independent tumor volume effect. Then, clinicians can judge it 
adequately using the imaging studies such as CT or bone scan as well as PSA and bone 
metabolic markers, an approach which is necessary to judge which treatment is most 
suitable for the CRPC patients.  
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Mechanisms of progression into CRPC related to an androgen-independent 
pathway 
Multiple molecular mechanisms which could account for the development of 
castration-resistant prostate cancer (CRPC) have been proposed [1] (Figure 1). One 
mechanism is an androgen receptor (AR)–independent pathway. When we look at many 
published papers on the immunohistochemistry of AR, the AR expression level is 
heterogeneous in high Gleason grade prostate cancer (PCa) tissue [2]. 
Androgen-independent growth might result from clonal expansion of such 
androgen-independent cells at the latter stage [3]. Even if AR is expressed in PCa cells, 
other factors, such as BCL-2 and EZH2, might dominantly act on cell proliferation 
irrespective of androgen deprivation therapy (ADT) [4, 5].  
 
Mechanisms of progression into CRPC related to adrenal androgen precursors 
 Recent clinical evidences that CYP17A inhibitors and second generation 
antiandrogens are very effective in CRPC after docetaxel treatment have clearly proven 
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that the androgen-AR signaling axis is an important pathway in the progression of PCa 
(Figure 1) [6] [7, 8]. The evidence obtained indicates that alterations of AR itself, which 
is either absent or at low concentration in the original androgen-dependent state, results 
in an androgen-hypersensitive situation where stimulation of PCa growth occurs at 
castrate levels of androgens [9, 10]. One of the AR alterations is AR mutation that 
results in promiscuous ligand specificity [11]. Therefore, in addition to its normal 
ligands, namely testosterone (T) and dihydrotestosterone (DHT), both androstenediol, 
estradiol, and pregnenolone, a common precursor of many steroids, can activate the AR 
and stimulate the proliferation of LNCaP cells that have such a mutated AR [12-14].  
Even if ADT is applied, the concentration of a precursor of T, namely androstenediol in 
PCa tissue is almost the same [14]. Once AR mutation occurs at T877A androstenediol 
will activate AR. The activation of AR is also a very critical factor for progression into 
CRPC. Overexpression of AR by gene amplification and enhanced transcription induces 
androgen-hypersensitivity [15, 16].  AR coactivators such as TIF2 and ARA55 also 
enhance androgen-hypersensitivity [17, 18]. Even if ADT decreases serum T to 
castration levels, androgen-hypersensitive PCa will adapt to the circumstance at the low 
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level of T in serum, begin to reproduce, and secrete prostate specific antigen (PSA) 
again.  
 
Synthesis of intratumoral androgens  
Not only AR alteration that adapts to the circumstance at the low level of 
serum T occurs after ADT in PCa, but also residual androgens in PCa tissue and 
metastasis sites affect altered AR. However, physiological concentrations of the adrenal 
androgen precursors dehydroepiandrosterone (DHEA) cannot activate AR nor stimulate 
proliferation of PCa [14]. It is necessary for DHEA to be converted into T or DHT in 
order to activate AR. Interestingly, DHT is present in PCa tissue after ADT. Specifically, 
when PCa patients are treated with ADT, serum T and DHT decreases to less than 
one-tenth of pretreatment levels [19]. However, T and DHT in PCa tissue are still 
present at 20 to 40% of pretreatment values [14, 19-23]. These residual androgens in 
PCa tissue after ADT continue to promote AR activation. This is accounted for by the 
observation that combination therapy with a LH-RH agonist, to block androgen 
production, and an antiandrogen, to block ligand binding to the AR, is more effective 
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for PCa treatment than either therapy alone [19, 24] [25]. Moreover, recent clinical trials 
using abiraterone acetate for post-docetaxel chemotherapy revealed that CYP17 
blockade by abiraterone acetate results in decline in PSA [26], suggesting androgen 
synthesis from adrenal precursors stimulates cancer progression even after docetaxel 
treatment. 
T and DHT in PCa tissue after medical or surgical castration are synthesized 
locally in the prostate from DHEA of adrenal origin [14, 19-23]. The metabolism from 
DHEA to DHT in peripheral target tissues depends upon the level of expression of 
various steroidogenic enzymes in the specific cell types of these tissues [27]. Adrenal 
DHEA is converted to T by 17-hydroxysteroid dehydrogenase (HSD17B) and 
3-hydroxysteroid dehydrogenase (HSD3B). T is then converted to DHT by 5-steroid 
reductase (SRD5A) in the prostate. HSD3B catalyzes almost exclusively the oxidation 
of 3-hydroxy-into 3-keto-5-androstene steroids (DHEA and 5-androstenediol are 
converted into androstenedione and testosterone by HSD3B, respectively) [28]. On the 
other hand, the HSD17Bs are responsible for the formation and inactivation of all active 
androgens: types 1, 3, 5, 7, 12 and 13 HSD17B catalyze the reductive reaction (DHEA 
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and androstenedione are converted into androstenediol and T, respectively) while types 
2, 4, 6 and 8 HSD17B catalyze the oxidative reaction (reverse conversion). SRD5A 
catalyzes the 5-reduction of 4-dione, T and other 4-ene-3-keto-steroids to the 
corresponding 5-dihydro-3-keto-steroids. These enzymes are localized in various 
peripheral tissues, including the prostate, with specific expression patterns in each tissue. 
For example, HSD3B and type 5 HSD17B were localized in basal cells of alveoli, 
stromal cells and endothelial cells of blood vessels of the prostate [29]. Various 
androgen-metabolising enzymes were also expressed in prostate cancer [30-33]. 
 
Alteration of androgen metabolism in PCa and CRPC 
Fung et al. have observed increased expression of the androgen synthesizing 
enzyme AKR1C3 (type 5 HSD17B), in PCa tissue [34] while Stanbrough et al. 
confirmed that ADT-resistant PCa and bone marrow metastases expressed increased 
levels of multiple genes responsible for androgen metabolism (HSD3B2, AKR1C3, 
SRD5A1, AKR1C2, AKR1C1 and UGT2B15) [35]. Especially, the mRNAs encoding 
HSD3B2, AKR1C3, and SRD5A1 that can make DHT from DHEA were overexpressed 
 8 
by 1.8, 5.3, and 2.1-fold in CRPC, respectively. These studies support the concept that 
PCa and CRPC tissues can perform local biosynthesis of T and DHT resulting in 
activation of the AR [36].  
Moreover, the activity of the steroidogenic enzymes is also affected by cytokines 
and growth factors. Activin A up-regulated expression of AKR1C3, inducing local 
conversion of androstenedione to T in LNCaP and VCaP PCa cell lines. The 
antiproliferative effects of activin were consequently counteracted in the presence of 
physiological levels of androstenedione. In addition, the ratio of inhibin A- and 
B-subunits to follistatin was increased in human PC tissue samples and inversely 
associated with metastasis-free survival [37]. Treatment of LNCaP cells with IL-6 
induced the expression of steroidogenic enzymes including CYP11A, HSD3B2, 
AKR1C3 and HSD17B3, and increased levels of T in lysates of cells grown in serum 
free media by 2-fold [38]. In DHEA-treated primary prostate stromal cells, transforming 
growth factor-1 (TGF1) induced time- and dose-dependent increases in metabolism 
of DHEA to androstenedione and testosterone. Moreover, TGF1-treated prostate 
stromal cells exhibited changes in the gene expression level of enzymes involved in 
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steroid metabolism including up-regulation of HSD3B, and down-regulation of type 5, 
and type 2 HSD17Bs [39]. Since TGF1 is one of the major cytokines that present in 
bone, androgen biosynthesis might be more increased in bone metastasis sites. IGF2 
that is overexpressed in CRPC tissue also increases expression of steroidogenesis 
enzymes, such as CYP17A1, AKR1C3, and HSD17B3, and increased de novo 
steroidogenesis resulting in AR activation [40].  
 
Microenvironment of PCa cells and steroidogenesis 
It remains unclear; however, in which cell types T and DHT are synthesized 
from DHEA in PCa tissue, although the products from DHEA and the relevant 
steroidogenic enzymes are definitively present in the prostate. If all steroidogenic 
enzymes are active in PCa cells, DHEA should be converted into T and DHT locally 
and activate AR and stimulate PCa cell proliferation. However, treatment with DHEA 
itself had little effect on AR activation and the proliferation of LNCaP and LAPC-4 
cells [14] [41]. Therefore, we needed to pay attention to not only PCa cells but also to 
the microenvironment of PCa cells, like stromal cells. Stromal cells can be involved in a 
 10 
paracrine fashion but the main site of conversion of DHEA into T is most likely the 
epithelial cells (intracrinology?).  In vitro, the secreted factors stay around with 
elevated concentrations but not in vivo? The enzymes transforming DHEA into T and 
DHT are possibly at a higher concentration in stromal and other cells cocultured with 
prostatic cell lines having low DHEA-converting ability. 
Arnold JT et al. demonstrated the importance of PCa-associated stromal cells on 
the conversion from DHEA into T [41]. When prostate cancer-associated (6S) stromal 
cells were added in coculture, DHEA stimulated LAPC-4 cell PSA protein secretion to 
levels approaching induction by DHT. Also, DHEA induced 15-fold more PSA mRNA 
in LAPC-4 cocultures than in monocultures. LAPC-4 proliferation was increased 2–3 
fold when cocultured with 6S stromal cells regardless of hormone treatment. 
DHEA-treated 6S stromal cells exhibited an increase in T secretion. We also explored 
the hypothesis that PCa stromal cells contribute to the biosynthesis of T and DHT in 
PCa [42]. DHEA alone had little effect on PSA promoter activity and the proliferation 
of LNCaP cells. However, the addition of normal prostate stromal cells (PrSC) or 
PCa-derived stromal cells (PCaSC) increased DHEA-induced PSA promoter activity via 
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AR activation in the LNCaP cells. Moreover, PCa-derived stromal cells and 
bone-derived stromal cells accelerated DHEA-induced PSA promoter activity 1.1-6.5 
fold more than the PrSC. Importantly, physiological concentrations of DHEA stimulate 
the proliferation of LNCaP cells in the presence of stromal cells, especially PCa-derived 
stromal cells. Biosynthesis of T and DHT from DHEA coculture of LNCaP cells with 
normal stromal cells and PCa-derived stromal cells was associated with AR activation 
(Figure 2, 3). 
We fortunately succeeded in culturing recurrent PCa-derived stromal cells 
(PCaSC-26) from the same primary PCa patient (PCaSC-8). We compared PCaSC-26 
with PCaSC-8 AR activity after treatment with DHEA. Recurrent PCaSC-26 enhanced 
DHEA-induced AR activity almost twice more in a LNCaP coculture system than 
PCaSC-8 (unpublished data). This data suggests that microenvironment of recurrent 
PCa tissue after ADT might support androgen metabolism to further enhance AR 
activity. Finally, the dual 5-reductase inhibitor dutasteride appears to function not only 
as 5-reductase inhibitor but also as HSD3B inhibitor in LNCaP cells. In a Phase II 
study of 3.5 mg dutasteride daily, an inhibitor of SRDA5, for CRPC during ADT has 
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shown that serum PSA level in several CRPC patients was improved by dutasteride 
treatment [43]. Auchus et al. identified the alternative pathway that synthesize 
5-androstane-3,17-diol (androstanediol), which is the proximal precursor of DHT in 
the testes of pouch young of the tammar wallaby and immature postnatal testes of 
several species. They called this phenomenon the ‘backdoor pathway’ to DHT 
formation instead of classical pathway where progesterone is converted to 
17-0H-progesterone, androstenedione, testosterone, and DHT sequentially [44]. 
Moreover, Locke et al. confirmed that this backdoor pathway as well as classical 
pathway existed by adding [3H]-progesterone to LNCaP cells and measuring several 
steroids that are related with backdoor pathway in LC-MS [45]. It is not clear how much 
DHT is synthesized through the backdoor pathway in CRPC after ADT when we 
consider the physiological level of progesterone in serum (~nM order) compared with 
the classical pathway.  
We experienced some precious cases in which SRDA5 might be associated with 
further progression of CRPC with bone metastases in our hospital. One CRPC patient 
with diffuse bone metastasis was treated 20 times with docetaxel and dexamethasone 
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(docetaxel treatment more than 10 times is approved in Japan) (Figure 4A). However, 
since PSA raised gradually and dysuria due to prostate swelling was observed, we 
treated with 0.5 mg daily dutasteride. Then, serum PSA decreased to 50% of baseline 
and was kept at a low level for 5 months. The other case was the CRPC patient whose 
life expectancy was speculated to be within 2 months because he had bulky lymph node 
mass in pelvis, severe pelvic bone metastasis, right pleural effusion, and dysuria by 
prostate swelling (Figure 4B). He was also treated with 0.5 mg daily dutasteride. The 
serum PSA level continued being stable for five months and CRP was decreased 
dramatically. It was speculated that synthesis of DHT was accelerated as a result of 
increased expression of SRDA5 and promoted a proliferation of PCa. 
Progesterone/17-0H-progesterone may also be quickly metabolized to a precursor of 
androsterone through activation of the backdoor pathway after SRDA5 activity is 
enhanced in some patients with CRPC. These cases suggested that the intracellular DHT 
concentration was important and not the serum levels.  
 
Reconsideration of the mechanism of progression to CRPC from androgen-naïve 
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PCa 
 We would like to consider a mechanism whereby androgen-naïve PCa 
progression to CRPC at a little more macro level (not molecular level) on the basis of 
clinical aspects. 
 PSA is an androgen responsive gene with a promoter that contains 3 
androgen-response elements (AREs). An ARE at 4.1 kb upstream of the transcription 
initiation site is an extremely strong enhancer that reacts with AR [46, 47]. Basically, 
the PSA gene is regulated merely by androgens and is regulated independently 
from cell proliferation. Therefore, ADT should cause a rapid decrease of the serum 
PSA level for one or two months in most PCa patients since the pretreatment 
concentrations of serum androgen are at less than a one-tenth of the pre ADT levels and 
can hardly activate AR, and AR cannot bind AREs of the PSA promoter even if PCa 
cells are not killed by ADT (PSA-androgen response phase) (Figure 5). A few months 
after initial treatment, many clinicians experience that the serum PSA level gradually 
decreases for a while (Tumor regression phase). ADT then regulates apoptosis-related 
genes and cell cycle-related genes through direct or indirect pathway during that period 
 15 
[48]. Therefore, PSA decreases according to the number of surviving cells which is 
gradually decreasing. Then, the serum PSA level becomes stable so that the number of 
cells that are going to die and cells that are going to reproduce again equilibrates 
(Proliferation quiescent phase). Finally, PCa cells activated during the period of ADT 
begin to reproduce again (CRPC phase).  
 As described above, when looking at the immunohistochemistry of AR in 
advanced PCa, AR expression is heterogeneous: even if there are many PCa cells 
overexpressing AR, the cells in which expression of AR decreases in PCa tissue. 
Accordingly, we have classified PCa cells into four types depending on functions of 
androgen: androgen-dependent cells, androgen-sensitive cells, androgen-hypersensitive 
cells, and androgen-independent cells (Figure 6A). Androgen-sensitivity and the ratio of 
each cell population should be different in each PCa patient. When first line ADT is 
applied, androgen-dependent cells will be killed and the number of androgen-sensitive 
cells will decrease, and then serum PSA decreases according to the ratio of cell type and 
AR activity (Figure 6B). However, androgen-hypersensitive cells and 
androgen-independent cells will survive in the presence of the castration level of 
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androgens in the serum. In some situations, androgen-sensitive cells may adapt 
themselves to the environment of low androgen concentrations and change into 
androgen-hypersensitive cells or androgen-independent cells (Figure 6B). Thus CRPC 
develops more and shifts to CRPC threatening life whereas what kind of cell types 
contributes to a development of CRPC predominantly is different in each patient 
(Figure 6C). 
 In this aspect, clinicians have to pay attention to the reason why serum PSA 
level is elevating in CRPC during ADT. It was difficult to monitor the longitudinal 
change of bone metastases until recently. However, the concept of measuring the 
quantitative level of bone metastasis by bone scan (Bone Scan Index, BSI) was 
developed [49]. Further, the software program for calculating BSI using the neural 
network system has also been developed using whole-body images with a Swedish 
database [50]. A Japanese multi-center database based on this software program 
significantly improved the diagnostic accuracy for estimating the quantitative level of 
bone metastasis [51]. Moreover, the changes in BSI have shown a close relationship 
with all bone metabolic markers but not with the serum PSA, and the BSI was 
 17 
confirmed to reflect the activity and extent of bone metastases [52]. We have measured 
the BSI calculated from bone scan of several patients who were treated with ADT 
(LH-RH agonist and bicalutamide) and show one case in Figure 7. Baseline serum PSA 
and BSI of the patient were 2163 ng/ml and 3.9%, respectively, and those declined to 
3.2 ng/ml and 0.12% within one year under ADT, respectively. However, the serum PSA 
level has begun to gradually increase from 15 months of initial treatment, and reached 
41.8 ng/ml at 20 months. Although the serum PSA level was still a one-50th of baseline 
at this point, BSI worsened to a level almost the same as at baseline (4.3%). What does 
this phenomenon mean? When PCa cells progresses to CRPC, it is considered that the 
serum PSA level is elevated for two mechanisms mainly. As mentioned above, one 
mechanism is involvement of the AR-related pathway. Especially, androgens of adrenal 
origin and their metabolites act on surviving PCa cells that became 
androgen-hypersensitive by some mechanisms and secretes PSA. In this pathway, 
strategies that block AR function, such as total androgen deprivation (TAD, castration, 
blocking adrenal androgen synthesis, and antiandrogens of a new generation) should be 
effective. Another mechanism is just a tumor volume effect (cell number effect). Even if 
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one PCa cell hardly secretes PSA (minimum basal level), the serum PSA level as all 
total amounts should increase if the number of PCa cells increases markedly. In this 
pathway, TAD will not be effective anymore because the basal PSA expression is not 
regulated by AR. Instead, chemotherapy or molecular target therapies may become 
strategies to control androgen-independent CRPC. In the patient of Figure 7, bone 
metastases suddenly worsened as compared with the increase of serum PSA level, thus, 
suggesting that the tumor volume effect is the main factor for progression to CRPC. 
How can clinicians distinguish AR-related pathways and tumor volume effect? One 
possibility is to conduct alternative antiandrogen therapy when serum PSA level begin 
to increase again [53]. Overall, PSA significantly decreased (50% or greater) in 83 of 
the 232 patients (35.8%) and also, a partial PSA response (PSA decrease 0% to 50%) to 
alternative antiandrogen therapy was observed in 59 of the 232 patients (25.4%). It will 
be useful to examine responsiveness of serum PSA by the alternative antiandrogen 
therapy in order to ascertain whether progress to CRPC passes through an AR-related 
pathway or not. If serum PSA level decreases by the alternative antiandrogen therapy, 
TAD should be the best way to decline serum PSA level and stabilize the symptom of 
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the patients for a long time.  
 
Conclusion 
 It is considered that PCa develops to CRPC during ADT by various genetic 
actions, but the mechanism playing a key role is the AR-related pathway. PCa cells 
mainly adapt themselves to the environment of low androgen concentrations and change 
into androgen-hypersensitive cells or androgen-independent cells. Androgens of adrenal 
origin and their metabolites synthesized in an intracrine fashion act on surviving PCa 
cells that became androgen-hypersensitive. Total androgen deprivation (TAD) can 
become an effective therapeutic strategy to control the androgen-related pathway. 
Clinically, it is important to ascertain whether elevation of serum PSA results from AR 
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Figure 1  Mechanisms of recurrence focusing on AR during ADT 
Blue and purple shapes represent AR-independent pathway and AR-mediated pathways, 
respectively. The two pathways sometimes overlap. 
 
Figure 2 Up-regulation of DHEA-induced AR activity (A) and activation of DHT 
biosynthesis by coculture of LNCaP cells with normal prostate-derived stromal cells 
(PrSC) and PCa-derived stromal cell (PCaSC-8) (B). 
 
Figure 3 Intracrine and paracrine androgen biosynthesis in PCa tissue after ADT 
 
Figure 4 Effect of dutasteride (dual SRDA5 inhibitor) on far advanced CRPC patients in 
Kanazawa University Hospital 
 
Figure 5 Serum PSA change by hormonal therapy and CRPC 
When PCa cells develop in CRPC, serum PSA elevation results from 2 reasons mainly: 
 28 
involvement of hypersensitive AR and androgens of adrenal precursor origin and tumor 
volume effect. 
 
Figure 6 Hypothetical mechanisms of development in CRPC from 
androgen-blockade-naïve PCa.  
A. Before ADT. Four kinds of cell populations can exist in PCa tissue. 
Androgen-independent cells grow very well regardless of the presence or absence of AR. 
The ratio among these kinds of cells can be different in each patient. B. After ADT. 
Three kinds of cell populations remain in PCa tissue including metastasis sites.  C. 
State of CRPC. Two kinds of cells remain in CRPC tissue. The effect of treatment 
changes according to which cell population is present predominantly in CRPC tissue. 
 
Figure 7 Result of serum PSA and bone scan index by bone scan 
A. Normalized bone scan. B. Graph of serum PSA and bone scan index.  Flu 
(flutamide), EMP (estramustine phosphate). 
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